AAPL336.13-0.87 (-0.26%) ▼|ABBV263.96-0.06 (-0.02%) ▼|ABT102.61+0.38 (+0.37%) ▲|ACN181.29-9.00 (-4.73%) ▼|ADBE248.92-3.75 (-1.48%) ▼|AMAT444.57+27.17 (+6.51%) ▲|AMD559.82+14.73 (+2.70%) ▲|AMGN385.65+5.87 (+1.55%) ▲|AMT173.98-1.60 (-0.91%) ▼|AMZN253.71+2.52 (+1.00%) ▲|AVGO357.61+10.31 (+2.97%) ▲|AXP311.56+0.39 (+0.13%) ▲|BA198.20+1.20 (+0.61%) ▲|BAC57.73-0.45 (-0.77%) ▼|BKNG167.90-2.62 (-1.54%) ▼|BLK1,069.78+15.82 (+1.50%) ▲|BMY63.06+0.22 (+0.35%) ▲|BNY153.79+0.77 (+0.50%) ▲|BRK-B509.77+0.57 (+0.11%) ▲|C131.77-0.93 (-0.70%) ▼|CAT808.99+10.42 (+1.30%) ▲|CL87.47-0.26 (-0.30%) ▼|CMCSA22.74-0.17 (-0.74%) ▼|COF202.43+0.39 (+0.19%) ▲|COP131.83-1.36 (-1.02%) ▼|COST895.31+1.38 (+0.15%) ▲|CRM237.92-4.93 (-2.03%) ▼|CSCO109.51-0.73 (-0.66%) ▼|CVS88.84-1.43 (-1.58%) ▼|CVX209.51-2.06 (-0.97%) ▼|DE683.99-1.64 (-0.24%) ▼|DHR211.81-0.69 (-0.32%) ▼|DIS102.67-2.68 (-2.54%) ▼|DUK117.53-1.01 (-0.85%) ▼|EMR149.92+2.52 (+1.71%) ▲|FDX303.65-2.23 (-0.73%) ▼|GD353.05-2.90 (-0.81%) ▼|GE314.27+0.80 (+0.26%) ▲|GEV940.33+15.40 (+1.67%) ▲|GILD150.11-0.78 (-0.52%) ▼|GM82.20-4.42 (-5.10%) ▼|GOOG344.41+0.73 (+0.21%) ▲|GOOGL349.54+2.21 (+0.64%) ▲|GS942.00-9.47 (-1.00%) ▼|HD299.98-2.53 (-0.84%) ▼|HON206.46-0.03 (-0.01%) ▼|IBM229.55-8.20 (-3.45%) ▼|INTC108.60-0.20 (-0.18%) ▼|INTU303.19-9.94 (-3.17%) ▼|ISRG393.33+9.79 (+2.55%) ▲|JNJ269.99-0.23 (-0.09%) ▼|JPM349.67+0.36 (+0.10%) ▲|KO88.25+0.19 (+0.22%) ▲|LIN460.40+1.92 (+0.42%) ▲|LLY1,152.93+0.49 (+0.04%) ▲|LMT533.38-4.71 (-0.88%) ▼|LOW192.49-1.70 (-0.88%) ▼|LRCX288.11+18.80 (+6.98%) ▲|MA565.24-0.49 (-0.09%) ▼|MCD248.24-0.24 (-0.10%) ▼|MDLZ60.85-1.19 (-1.92%) ▼|MDT92.13-0.64 (-0.69%) ▼|META665.75-16.56 (-2.43%) ▼|MMM165.89+1.18 (+0.72%) ▲|MO69.52-0.18 (-0.26%) ▼|MRK146.87-0.28 (-0.19%) ▼|MS202.58-0.94 (-0.46%) ▼|MSFT493.78-3.97 (-0.80%) ▼|MU1,015.80+38.30 (+3.92%) ▲|NEE80.47-0.81 (-1.00%) ▼|NFLX71.79-3.52 (-4.67%) ▼|NKE35.51-0.85 (-2.34%) ▼|NOW135.47-3.00 (-2.17%) ▼|NVDA222.27+2.93 (+1.34%) ▲|ORCL147.61-2.98 (-1.98%) ▼|PEP129.75-3.91 (-2.93%) ▼|PFE27.66+0.02 (+0.07%) ▲|PG146.39-1.16 (-0.79%) ▼|PLTR177.64+1.40 (+0.79%) ▲|PM188.62-1.86 (-0.98%) ▼|QCOM177.72-10.99 (-5.82%) ▼|RTX194.00+0.46 (+0.24%) ▲|SBUX95.83-0.84 (-0.87%) ▼|SCHW105.25+0.62 (+0.59%) ▲|SO85.52-1.24 (-1.43%) ▼|SPG205.32+0.85 (+0.42%) ▲|T25.40+0.01 (+0.04%) ▲|TMO651.45-6.87 (-1.04%) ▼|TMUS168.18+1.73 (+1.04%) ▲|TSLA364.27-1.93 (-0.53%) ▼|TXN266.64+8.50 (+3.29%) ▲|UBER70.50-0.37 (-0.52%) ▼|UNH376.90+1.69 (+0.45%) ▲|UNP279.37-3.11 (-1.10%) ▼|UPS99.06-1.11 (-1.11%) ▼|USB60.06-0.19 (-0.32%) ▼|V368.29-1.64 (-0.44%) ▼|VZ48.09-0.24 (-0.50%) ▼|WFC86.12-0.77 (-0.89%) ▼|WMT106.73-0.06 (-0.06%) ▼|XOM163.54+0.27 (+0.17%) ▲|AAPL336.13-0.87 (-0.26%) ▼|ABBV263.96-0.06 (-0.02%) ▼|ABT102.61+0.38 (+0.37%) ▲|ACN181.29-9.00 (-4.73%) ▼|ADBE248.92-3.75 (-1.48%) ▼|AMAT444.57+27.17 (+6.51%) ▲|AMD559.82+14.73 (+2.70%) ▲|AMGN385.65+5.87 (+1.55%) ▲|AMT173.98-1.60 (-0.91%) ▼|AMZN253.71+2.52 (+1.00%) ▲|AVGO357.61+10.31 (+2.97%) ▲|AXP311.56+0.39 (+0.13%) ▲|BA198.20+1.20 (+0.61%) ▲|BAC57.73-0.45 (-0.77%) ▼|BKNG167.90-2.62 (-1.54%) ▼|BLK1,069.78+15.82 (+1.50%) ▲|BMY63.06+0.22 (+0.35%) ▲|BNY153.79+0.77 (+0.50%) ▲|BRK-B509.77+0.57 (+0.11%) ▲|C131.77-0.93 (-0.70%) ▼|CAT808.99+10.42 (+1.30%) ▲|CL87.47-0.26 (-0.30%) ▼|CMCSA22.74-0.17 (-0.74%) ▼|COF202.43+0.39 (+0.19%) ▲|COP131.83-1.36 (-1.02%) ▼|COST895.31+1.38 (+0.15%) ▲|CRM237.92-4.93 (-2.03%) ▼|CSCO109.51-0.73 (-0.66%) ▼|CVS88.84-1.43 (-1.58%) ▼|CVX209.51-2.06 (-0.97%) ▼|DE683.99-1.64 (-0.24%) ▼|DHR211.81-0.69 (-0.32%) ▼|DIS102.67-2.68 (-2.54%) ▼|DUK117.53-1.01 (-0.85%) ▼|EMR149.92+2.52 (+1.71%) ▲|FDX303.65-2.23 (-0.73%) ▼|GD353.05-2.90 (-0.81%) ▼|GE314.27+0.80 (+0.26%) ▲|GEV940.33+15.40 (+1.67%) ▲|GILD150.11-0.78 (-0.52%) ▼|GM82.20-4.42 (-5.10%) ▼|GOOG344.41+0.73 (+0.21%) ▲|GOOGL349.54+2.21 (+0.64%) ▲|GS942.00-9.47 (-1.00%) ▼|HD299.98-2.53 (-0.84%) ▼|HON206.46-0.03 (-0.01%) ▼|IBM229.55-8.20 (-3.45%) ▼|INTC108.60-0.20 (-0.18%) ▼|INTU303.19-9.94 (-3.17%) ▼|ISRG393.33+9.79 (+2.55%) ▲|JNJ269.99-0.23 (-0.09%) ▼|JPM349.67+0.36 (+0.10%) ▲|KO88.25+0.19 (+0.22%) ▲|LIN460.40+1.92 (+0.42%) ▲|LLY1,152.93+0.49 (+0.04%) ▲|LMT533.38-4.71 (-0.88%) ▼|LOW192.49-1.70 (-0.88%) ▼|LRCX288.11+18.80 (+6.98%) ▲|MA565.24-0.49 (-0.09%) ▼|MCD248.24-0.24 (-0.10%) ▼|MDLZ60.85-1.19 (-1.92%) ▼|MDT92.13-0.64 (-0.69%) ▼|META665.75-16.56 (-2.43%) ▼|MMM165.89+1.18 (+0.72%) ▲|MO69.52-0.18 (-0.26%) ▼|MRK146.87-0.28 (-0.19%) ▼|MS202.58-0.94 (-0.46%) ▼|MSFT493.78-3.97 (-0.80%) ▼|MU1,015.80+38.30 (+3.92%) ▲|NEE80.47-0.81 (-1.00%) ▼|NFLX71.79-3.52 (-4.67%) ▼|NKE35.51-0.85 (-2.34%) ▼|NOW135.47-3.00 (-2.17%) ▼|NVDA222.27+2.93 (+1.34%) ▲|ORCL147.61-2.98 (-1.98%) ▼|PEP129.75-3.91 (-2.93%) ▼|PFE27.66+0.02 (+0.07%) ▲|PG146.39-1.16 (-0.79%) ▼|PLTR177.64+1.40 (+0.79%) ▲|PM188.62-1.86 (-0.98%) ▼|QCOM177.72-10.99 (-5.82%) ▼|RTX194.00+0.46 (+0.24%) ▲|SBUX95.83-0.84 (-0.87%) ▼|SCHW105.25+0.62 (+0.59%) ▲|SO85.52-1.24 (-1.43%) ▼|SPG205.32+0.85 (+0.42%) ▲|T25.40+0.01 (+0.04%) ▲|TMO651.45-6.87 (-1.04%) ▼|TMUS168.18+1.73 (+1.04%) ▲|TSLA364.27-1.93 (-0.53%) ▼|TXN266.64+8.50 (+3.29%) ▲|UBER70.50-0.37 (-0.52%) ▼|UNH376.90+1.69 (+0.45%) ▲|UNP279.37-3.11 (-1.10%) ▼|UPS99.06-1.11 (-1.11%) ▼|USB60.06-0.19 (-0.32%) ▼|V368.29-1.64 (-0.44%) ▼|VZ48.09-0.24 (-0.50%) ▼|WFC86.12-0.77 (-0.89%) ▼|WMT106.73-0.06 (-0.06%) ▼|XOM163.54+0.27 (+0.17%) ▲|
19.3 C
New York
Sunday, September 20, 2026

Tag: 6

newssourceFORcompanyinformationcontent1releasesmarket

Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers – FTRE

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fortrea Holdings, Inc. ("Fortrea" or the...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published...

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

Monster Energy’s Marine Cabirou Takes First Place at 2025 UCI Downhill Mountain Bike World Cup in Val Di Sole

31-Year-Old Troy Brosnan from Adelaide, South Australia, Takes 2nd Place in Elite Men Division24-Year-Old Thibaut Daprela from France Claims 3rd Place VAL DI SOLE, Italy,...

New Subsidiary in Mexico: SOUEAST Debuts S06 i-DM, S07, S09, Pushes Advanced New Energy Tech

MEXICO CITY, June 22, 2025 (GLOBE NEWSWIRE) -- On June 18, 2025, at the grand brand and products launch ceremony in Centro Citibanamex, Mexico, SOUEAST announced its entry to Mexican market and unveiled three new models, attracting wide attention, signaling a significant breakthrough in SOUEAST's Latin American expansion.

Nueva filial en México: SOUEAST presenta los modelos S06 i-DM, S07 y S09, e impulsa tecnología de nuevas energías

MEXICO CITY, June 22, 2025 (GLOBE NEWSWIRE) -- El 18 de junio de 2025, durante la gran ceremonia de lanzamiento de marca y productos en el Centro Citibanamex, México, SOUEAST anunció su entrada al mercado mexicano y presentó tres nuevos modelos, atrayendo una gran atención y marcando un avance significativo en la expansión de SOUEAST en América Latina.

NICKELODEON KIDS’ CHOICE AWARDS 2025 HIGHLIGHTS AND WINNERS

Share It: @Nickelodeon @KidsChoiceAwards #KCA ** Click HERE to access interviews, clips, photos and footage from the show. HOLLYWOOD, Calif., June 21, 2025 /PRNewswire/ -- Nickelodeon Kids' Choice...

Monster Energy’s Arisa Trew (Skateboarding) and Ryan Williams (BMX) Earn Dominant Victories on Day 1 of X Games Osaka 2025

-15-Year-Old Arisa Trew from Palm Beach, Australia, Claims Gold in Women's Skateboard Vert, Ties All-Time Record for Most X Games Gold Medals in Women's...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy

Kaanch Network Presale Positions Project Among Top Altcoins and Best Crypto Opportunities of 2025

DUBAI, United Arab Emirates, June 21, 2025 (GLOBE NEWSWIRE) -- Kaanch Network’s token is set to be listed on BitMart and LBank exchanges on June 30th, an important milestone in the project’s mission to revolutionize decentralized finance and asset management. Built on a scalable and affordable Layer 1 blockchain with real-world applications, Kaanch offers developers, business owners, and investors a compelling platform for growth in 2025 and beyond.

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit...

SAN DIEGO, June 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI’s top executives with violations of the Securities Exchange Act of 1934.

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags6

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers